Sheares to head Merck marketing as McGlynn leads vaccines

Share this article:
Merck reshuffled its senior management, consolidating sales and marketing leadership for U.S. human health under president Bradley Sheares and moving Margaret McGlynn, formerly co-president of U.S. human health, to head up its vaccines division.

McGlynn had led hospital and specialty sales, marketing, marketing services and managed care, all areas that will now be handled by Sheares. She replaces Adel Mahmoud as president of Merck Vaccines and takes on responsibility for Merck's joint venture with Sanofi Aventis. Mahmoud faces mandatory retirement on Sep. 6, when he turns 65. He will serve on Merck's management committee as chief medical advisor for vaccines and infectious diseases.

Sheares will assume responsibility for the entire U.S. human health division.

Judy Lewent, executive vice president and chief financial officer, will assume responsibility for strategic planning, in addition to her previous duties which include business development, licensing, Merck Capital Ventures and the joint ventures with Merial and Johnson & Johnson, AstraZeneca and DuPont.

Lewent hands responsibility for human health Asia Pacific off to David Anstice, who previously headed Japan, Australia and New Zealand, as well as the firm's joint venture with Schering-Plough. Per Wold-Olsen, president of human health for Europe, the Middle East and Africa, will also take on Canada and Latin America. He continues to manage worldwide human health marketing and Merck's new business efforts in India. 
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...